Navigation Links
Novexel to Present Five Posters at the Joint Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Disease Society of America (ICAAC/IDSA) Meeting
Date:10/24/2008

PARIS, October 24 /PRNewswire/ -- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces that its pipeline will be the subject of five posters at the joint annual meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Disease Society of America (48th annual ICAAC/IDSA 46th annual meeting), which takes place in Washington, DC, October 25-28, 2008.

NXL104, Novexel's broad spectrum class A and C ss-lactamase inhibitor, will be the subject of three posters. In vitro data will be presented showing that a ceftazidime/NXL104 combination is rapidly bactericidal against a range of beta-lactamase-producing Enterobacteriaceae and that one of the most important factors affecting the pharmacodynamics of the combination is maintaining a critical concentration of the inhibitor (NXL104) that suppresses beta-lactamase activity. (Poster A-023). A second poster describes the use of a ceftazidime/NXL104 disk diffusion assay for the detection and identification of the Klebsiella pneumoniae carbapenemase enzyme (KPC) in Enterobacteriaceae (Poster D-291b). The third poster details a microbroth dilution quality control study on ceftazidime/NXL104 (Poster F-2665).

The potent in vitro activity of NXL103, a novel oral streptogramin, will be presented against a range of staphylococci, including vancomycin intermediate and resistant isolates (Poster F1-365).

A fifth poster covers the anti-staphylococcal activity of NXL101, a bacterial gyrase inhibitor, now discontinued.

All posters will be available for download from Novexel's web site (http://www.novexel.com) shortly after the close of ICAAC.

About Novexel

Novexel is a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The ever increasing resistance to marketed antibiotics has led to a clear need for novel drugs that are active against multi-drug resistant bacteria. Novexel's products are targeting the global hospital antibiotic market, which was worth an estimated $15bn in 2007 according to information derived from the IMS Midas(R) database.

Novexel currently has two novel antibacterials in Phase II clinical development. These are the injectable beta-lactamase inhibitor, NXL104, which is being developed in combination with the cephalosporin antibiotic ceftazidime for serious Gram negative infections, and the oral streptogramin antibiotic, NXL103, for the treatment of Gram positive infections, with a focus on treatment in the hospital setting and intravenous (IV) to oral switch. Novexel has three further programmes in preclinical development, NXL105, a novel anti-Pseudomonal antibiotic, NXL201, a novel echinocandin antifungal agent, and NXL104 in combination with ceftaroline. This latter product is being developed by our partner, Forest Laboratories, solely for North American markets.

Novexel was created in December 2004 as an independent spin-out of the sanofi-aventis (Euronext Paris: SAN, NYSE: SNY) anti-infectives unit. Novexel has a team of 50 employees with significant experience in anti-infective research and development, who are located in Paris, France and Philadelphia, USA.

For further information please contact:

Novexel

Gordon Waldron, CFO

Tel: +33-1-5714-0777

gordon.waldron@novexel.com

Citigate Dewe Rogerson

Amber Bielecka/David Dible/Nina Enegren

Tel.: +44(0)207-638-95-71

amber.bielecka@citigatedr.co.uk


'/>"/>
SOURCE Novexel
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
2. Mpex Pharmaceuticals Presents New Data on MP-376 in Cystic Fibrosis
3. Nerviano Medical Sciences Invited by EORTC-NCI-AACR to Present the State-of-the-Art of Aurora
4. Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium
5. Thermogard XP(TM) Studies to Be Presented at American Society of Anesthesiologists Annual Meeting
6. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
7. Cytopia Scientific Presentations on JAK2 Inhibitor Program
8. Paratek to Present Clinical Data in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
9. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
10. Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress
11. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)...  Cogentix Medical, Inc. (NASDAQ: CGNT), a global ... Uro/Gyn and Gynecology markets with innovative and proprietary ... the Company as Senior Vice President, Marketing & ... Keswani will report directly to Darin Hammers ... is delighted that Ash has joined the Cogentix ...
(Date:4/20/2017)... Research and Markets has announced the addition ... Addressing Production Complexities Through Risk Management and Quality by ... ... Market Prospects: Overcoming Production Complexities Through Risk Management and ... current trends in the global biosimilars market, with a ...
(Date:4/20/2017)... , April 20, 2017  CVS Pharmacy, ... today unveiled a new store design to enhance ... of healthier food, health-focused products and expanded beauty ... to help customers discover new offerings. Together with ... next evolution of the customer experience at CVS ...
Breaking Medicine Technology:
(Date:4/22/2017)... (PRWEB) , ... April 22, ... ... Administration of Eastern Pennsylvania has named PROSHRED® Security of Philadelphia its ... Heron-Doerr, PROSHRED® Philadelphia specializes in providing information destruction , recycling, ...
(Date:4/21/2017)... ... ... Providing broad access to life-saving drugs and rewarding the innovators who develop ... address this problem. , That was the message from Dana Goldman, PhD, Leonard D. ... of Southern California, who served as the keynote speaker for Western University of Health ...
(Date:4/21/2017)... ... April 21, 2017 , ... Brady (NYSE:BRC), a global leader in ... and B-7569 vinyl label materials received certification for the BS5609 British Marine ... remain intact and legible, for use on chemical drums shipped by sea. ...
(Date:4/21/2017)... ... 2017 , ... The VIA Agency , a full-service ... Theravent, Inc. , the makers of a revolutionary new device clinically proven to ... working to expand distribution in anticipation of a national launch. VIA will be ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... exciting new partnership with the highly regarded and well renowned Asian distributor, Discovery ... myTAP & myTAP PAP Nasal Pillow Mask, and will stabilize and strengthen Airway’s ...
Breaking Medicine News(10 mins):